common side effects of retatrutide Lilly's shows 28% weight loss, but increased Retatrutide side effects - Hair

Nixon and Rubinsztein, 2024)

SLU-PP-332 is a research compound currently being explored in metabolic and endurance-related studies

Retatrutide is not FDA approved, not EMA approved, and has no approved prescription pathway as of April 2026

In these studies, insulin adjustments were minimized in order to isolate the SYMLIN effect with insulin adjustments allowed, at the investigator's discretion, when excessive hypoglycemia was encountered

Research suggests microdosing may help correct blood sugar instability and insulin sensitivity even before significant weight loss occurs

We look at your health, your goals, and your lifestyle to make sure GLP-1 weight loss is safe, effective, and aligned with what your body needs for real, lasting progress